Greenbrook

Greenbrook is a healthcare startup dedicated to providing advanced and compassionate mental health care solutions. The company operates healthcare centers that offer repetitive transcranial magnetic stimulation therapy (TMS) to address major depressive disorder (MDD) and other neurological conditions. Through electromagnetic stimulation targeting specific mood-regulating brain areas, Greenbrook aims to rejuvenate lives. Additionally, the company offers Spravato to address depressive symptoms in adults with MDD, especially those experiencing suicidal thoughts or treatment-resistant depression. Greenbrook's comprehensive treatment experience includes managing insurance coverage and logistics while keeping patients informed and engaged throughout the process. Founded in 2011, Greenbrook received a significant Post-IPO Equity investment of $1.20M on 22 February 2024. This infusion of capital is indicative of investor confidence in the company's mission and potential for growth in the mental healthcare sector. While the details of the investor(s) behind this investment are currently unavailable, this funding is expected to propel Greenbrook's innovative solutions and patient-centered approach to mental health care to greater heights.